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Myeloid-derived suppressor cells (MDSC) are well-known key negative regulators of
the immune response during tumor growth, however scattered is the knowledge
of their capacity to influence and adapt to the different tumor microenvironments
and of the markers that identify those capacities. Here we show that the secreted
protein acidic and rich in cysteine (SPARC) identifies in both human and mouse
MDSC with immune suppressive capacity and pro-tumoral activities including the
induction of epithelial-to-mesenchymal transition (EMT) and angiogenesis. In mice
the genetic deletion of SPARC reduced MDSC immune suppression and reverted
EMT. Sparc−/− MDSC were less suppressive overall and the granulocytic fraction was
more prone to extrude neutrophil extracellular traps (NET). Surprisingly, arginase-I and
NOS2, whose expression can be controlled by STAT3, were not down-regulated in
Sparc−/− MDSC, although less suppressive than wild type (WT) counterpart. Flow
cytometry analysis showed equal phosphorylation of STAT3 but reduced ROS production
that was associated with reduced nuclear translocation of the NF-kB p50 subunit
in Sparc−/− than WT MDSC. The limited p50 in nuclei reduce the formation of
the immunosuppressive p50:p50 homodimers in favor of the p65:p50 inflammatory
heterodimers. Supporting this hypothesis, the production of TNF by Sparc−/− MDSC
was significantly higher than by WT MDSC. Although associated with tumor-induced
chronic inflammation, TNF, if produced at high doses, becomes a key factor in mediating
tumor rejection. Therefore, it is foreseeable that an unbalance in TNF production could
skewMDSC toward an inflammatory, anti-tumor phenotype. Notably, TNF is also required
for inflammation-driven NETosis. The high level of TNF in Sparc−/− MDSC might explain
their increased spontaneous NET formation as that we detected both in vitro and in vivo,
in association with signs of endothelial damage. We propose SPARC as a new potential
marker of MDSC, in both human and mouse, with the additional feature of controlling
MDSC suppressive activity while preventing an excessive inflammatory state through the
control of NF-kB signaling pathway.
Keywords: SPARC, myeloid-derived suppressor cells, breast cancer, neutrophil, neutrophil extracellular traps
Sangaletti et al. SPARC Activities in Myeloid Cells
INTRODUCTION
Tumor growth implies a systemic state of immune suppression,
also characterized by bone marrow (BM) expansion and
circulation of myeloid cells able to suppress adaptive immune
responses through a variety of mechanisms (1, 2). The so-called
myeloid-derived suppressor cells (MDSC) are a heterogeneous
pool of myeloid cells, mainly composed by two subsets, the
monocytic (M)-MDSC and the polymorphonuclear (PMN)-
MDSC, characterized by different phenotypic markers, which
are also distinct between human and mouse. The two subsets
expand differently and are endowed with different suppressive
activities depending on the specific tumor types (3, 4). Persistent
tumor release of growth factors and cytokines (such as G-CSF,
GM-CSF, and VEGF), promote MDSC production in the BM,
whereas tumor release of chemokines (i.e., CCL2, CXCL12)
recruits them within the tumor microenvironment (TME) (5,
6). Once in the TME, MDSC acquire suppressive activity
through the chronic sensing of inflammatory cytokines and
damage-associated molecular patterns (DAMP). PMN-MDSC
are phenotypically almost indistinguishable from neutrophils,
which also share several functions in favor of tumor growth
and dissemination. M-MDSC are instead similar to monocytes
and are characterized by high plasticity: in the TME they can
differentiate in macrophages and dendritic cells (7, 8).
Neutrophils can chaperone circulating tumor cells that,
through a VCAM1-mediated embrace, gain proliferative capacity
while in circulation (9). Notably similar interaction, but via beta1
integrin, is retained by PMN even when dying of NETosis, a
peculiar type of cell death releasing neutrophils extracellular traps
(NETs) (10). NETs are double strand DNA threads decorated
with anti-microbial proteins that are extruded by neutrophils to
control bacterial and fungi infections. Several stimuli (e.g., IFN,
TNF, IL-8, and DAMP) initiate NETosis by binding to neutrophil
receptors (e.g., Fc receptors, TLRs) (11). An aberrant NET
production has been reported in autoimmune conditions, such
as systemic vasculitis and systemic lupus erythematosus (12).
Many papers are now describing NET in the context of cancer
(10, 13). In solid tumors NET have been shown in clinical samples
of triple-negative human breast cancer (TNBC). Using murine
models of TNBC Park et al. showed that NET stimulate invasion
and migration of breast cancer cells. Inhibiting NET formation
or digesting NET with DNAse I in vivo reduced lung metastasis.
Furthermore, NET can wrap circulating tumor cells (CTC)
through a β1 integrin-mediated mechanism or promote cancer
cell awakening through extracellular matrix (ECM) remodeling
(14, 15). It remains undetermined whether NETs, which are
decorated with proteolytic enzymes active on endothelial cells in
case of vasculitis, can leave tumor cells unhurt upon their contact.
In this context, we have published that inflammatory
neutrophils isolated from subcutaneous agar implants
spontaneously extrude NETs (16) and display cytostatic
activity against cultured tumor cells (17).
Tumor growth is also associated with aberrant extracellular
matrix (ECM) deposition. An increase in collagen content
enhances ECM stiffness with consequences on tumor cell survival
and migration (18). Other than contributing to the biological
and clinical heterogeneity of solid cancers the ECM can directly
affect tumor cell as well as immune cell behavior within the
TME (19). When activated, immune cells express the ITIM-
receptor LAIR-1 that specifically binds to Gly-Pro-Hyp collagen
conserved motives (20). The triggering of this receptor activates
a negative inhibitory signal that blocks cell activation including
NET formation and ROS production (21, 22) We have recently
demonstrated that an aberrant ECM deposition characterized
by secreted protein acidic and rich in cysteine (SPARC) and
high collagen content promotes the recruitment of suppressive
myeloid cells (23). SPARC belongs to the class of matricellular
proteins with regulatory functions tuning different biological
processes, including migration, proliferation, adhesion and cell
survival (24). Although not strictly endowed with structural
functions, matricellular proteins can control ECM stiffness and
composition. In Sparc−/− mice, collagen fibers are smaller and
disorganized (25, 26) whereas SPARC overexpression promotes
collagen fiber deposition and increases ECM stiffness, which in
turn activates the process of MDSC recruitment in the TME (23).
These data indicate that an ECM rich in SPARC can modulate
myeloid cell functions. Less studied and appreciated is the role of
matricellular proteins when produced directly by myeloid cells.
On this line we have previously shown that another matricellular
protein, osteopontin (OPN), when produced by M-MDSC as
intracellular protein (iOPN), tunes MDSC suppressive function,
modulating the expression of arginase-1, IL-6 and phospho-
Stat3 (27). Here we studied the role of SPARC as marker of
human and mouse MDSC and its possible regulatory function on
their activity.
MATERIALS AND METHODS
Animals, Cell Lines, and in vivo
Experiments
BALB/cAnNCrl mice (BALB/c) were purchased from Charles
River Laboratories (Calco). All experiments involving animals
were approved by the Ministry of Health (INT 16_2016,
authorization number 288/2017-PR). Sparc−/− mice on a
BALB/c background were obtained in our laboratory as
previously described (25). The mammary carcinoma cell
line SN25A was obtained from SPARC-deficient mice that
spontaneously developed mammary tumors due to the
expression of the rat HER2/neu oncogene (BALB/c; SPARC
< tm1Hwe > Tg(MMTV-Erbb2)NK1Mul/J), whereas the N3D
cell line was derived from transgenic Her2/Neu mice (BALB/c-
Tg(MMTV-Erbb2)NK1Mul/J). Both cell lines were infected with
the retroviral vector LXSPARCSH to over-express SPARC and
the co-isogenic cell lines, SN25ASP and N3DSP, were obtained
(23). Mice were injected into the mammary fat pad with SN25A,
N3D, N3DSP (all at the dose of 2x10∗5 cells) and SN25ASP (10∗6
cells) cell lines and tumors collected when they reached a 10
mm diameter.
Patient Samples and Gene Expression Data
Peripheral Blood was obtained from consecutive breast cancer
patients (12 cases) to be surgically resected at Fondazione
IRCCS Istituto Nazionale Tumori. The study was approved
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by the Medical Ethics Committee (Auth. Number 167/17),
and all clinical data were obtained after receiving informed
consent, according to institutional rules. Confocal microscopy
analysis was performed onto consecutive primary breast tumors
surgically resected at Fondazione IRCCS Istituto Nazionale
dei Tumori.
Flow Cytometry Analysis
For FACS analysis primary tumors or spleens were collected
and maintained in DMEM−10%FBS, then minced and filtered
through a 40 µm-pores cell strainer (BD). Red blood cells
were removed using ACK lysis buffer (ammonium chloride
potassium). Cells were Fc-blocked using CD16/32 antibody
(eBioscience) before staining. Antibodies used were: CD45.2; Gr-
1; CD11b; Ly6G, and Ly6C (all from eBioscience). Samples were
acquired using a BD LSR II Fortessa instrument and analyzed
with FlowJo software (TreeStar). All samples are analyzed in
single; in each experiment at least 3–4 samples were analyzed for
each group.
PBMC Flow Cytometry and Cell Sorting
Blood samples were collected in heparin and peripheral blood
mononuclear cells (PBMCs) were obtained by diluting whole
blood samples patients 1:2 with PBS 1X and subsequently
subjected to a density gradient stratification. Briefly, diluted
whole blood samples was carefully layered onto Histopaque-
1077 Ficoll (Sigma- Aldrich) and centrifuged at 1,800 rpm
for 30min at room temperature without brake. Finally, the
lymphocyte-enriched ring at the interface was transferred into a
new collection tube and washed with PBS 1X by centrifugation at
1,200 rpm for 5min. PBMCs were then stained and analyzed by
BD LSR II Fortessa instrument. For MDSC characterization 106
PBMCwere stained with the following Ab: Lin1 (FITC); HLA-DR
(APC eFl780), CD11b (BB700), CD14 (FITC), CD15 (BV650),
CD16 (Pe-Cy7), and CD33 (PE) (Supplementary Table 1). Total
MDSC were sorted from PBMC according to HLA-DR, CD33
and CD11b expression. Cells were sorted using a FACSAria
BD Instrument.
MDSC Isolation From Spleen and in vivo
Tumors for RT-PCR
For MDSC isolation, spleens and mammary lesions from tumor-
bearing mice (or naive mice as controls for spleen MDSC), were,
minced and filtered to obtain a single cell suspension. Red blood
cells were lysed by ACK lysis buffer and MDSC were sorted with
FACSAria BD Instrument with the following antibodies: CD45,
CD11b, Ly6G, and Ly6C (all from Ebioscience).
RNA Extraction and RT-PCR
For quantitative RT-PCR, myeloid cells were lysed with TRIzol
(Invitrogen Life Technologies) and RNA was extracted using
the RNeasy Kit (Qiagen). DNA contaminants were removed
by treatment with DNase I. cDNA was reverse transcripted
from 1 µg of total RNA. PCR was performed using TaqMan
Universal PCRmaster mix (Applied Biosystems, Foster City, CA,
USA) and a target gene assay mix containing sequence-specific
primers for the Arginase1, Sparc, TGFb, TNF, NOS-2, and Stat3
genes. Gene-specific primers were purchased from Applied
Biosystems (Tnf Mm00443260_g1; Arg Mm00475989; Stat3
Mm01219775_m1; Sparc Mm00486332_m1; Vegf Mm01281449;
Nos2 Mm00440502_m1; Gapdh Mm99999915_g1). The
reactions were set up according to the standard TaqMan qPCR
conditions reported in the Applied Biosytems protocol and
were performed in duplicate for each sample. The qPCR assays
were run using the ABI PRISM R© 7900 Fast Real Time PCR
system and the ABI PRISM 7900 HT Sequence Detection System
(Applied Biosystems), and the result data were analyzed with
SDS Software 2.3 (Applied Biosystems). The mRNA level of
the target genes was quantified by measuring the CT value
to determine its relative expression. The results are reported
using the fold change in the gene expression of the target genes
relative to the internal control gene (GAPDH). The mean-fold
change in target gene expression was calculated as 2-11CT,
where DDCT=[(CT,Target - CT,GAPDH)sample-(CT,Target -
CT,GAPDH)] internal control.
Immunohistochemistry
and Immunofluorescence
Histological and immunohistochemistry analyses of
human and mouse tissues were performed as described
previously (23). All antibodies that have been used are
listed in Supplementary Table 2. For double-marker
immunofluorescence stainings in which primary antibodies of
the same made were adopted, the tyramide signal amplification
system Opal multiplex IHC kit (Lot number 2395285,
PerkinElmer Inc.) was adopted. Briefly, after deparaffinization,
antigen retrieval was performed using microwave heating and
a pH9 buffer and the first primary antibody was incubated
overnight at 4◦C (monoclonal anti-Human Osteonectin/Sparc,
Clone ON1-1, 1:500, Life technologies). Immunofluorescence
labeling was achieved by incubating with a specific secondary
antibody, followed by the addition of one selected Opal
fluorophore and microwave treatment in pH9 buffer. The
same procedure was repeated for the second primary antibody
for 90min at room temperature (monoclonal anti-Human
CD33, Clone PWS44, 1:100, Novocastra), using a different Opal
fluoprophore and DAPI nuclear counterstain. All the sections
were analyzed under Zeiss Axio Scope A1 optical microscope
(Zeiss, Germany) and microphotographs were collected using
an Axiocam 503 Color digital camera with the ZEN2 imaging
software (Zeiss Germany).
In vitro Suppressive Assay
Myeloid derived suppressor cells were purified using
CD11b-conjugated microbeads (for overall population)
and Myeloid-Derived Suppressor Cell Isolation Kit [for
separation of the two subsets (Miltenyi Biotec)] following the
manufacturer’s instructions.
For in vitro suppression assay, 4 × 105 naïve BALB/c
splenocytes have been labeled with CFSE (Carboxyfluorescein
Succinimidyl ester; SIGMA Aldrich) and co-cultured with the
different MDSC population at different ratio in presence of
2µg/ml of soluble anti-CD3 and 1µg/ml of anti-CD28 to activate
lymphocytes. Each sample was seeded in triplicate. Proliferation
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of CD4 and CD8T cells has been assessed 2 and 3 days later,
by flow cytometry evaluating CFSE dilution in the CD4+ and
CD8+ gated populations. Results are shown as percentage of
proliferated cells.
ROS Detection
The detection of ROS was performed on the overall population
of myeloid derived suppressor cells purified using CD11b-
conjugated microbeads using the CellROX R© Green Reagent (Life
technologies)a fluorogenic probe for measuring ROS in live cells.
Oxidation of the cell-permeant dye by ROS generate a bright
green fluorescence detectable at FACS.
Evaluation of p50 and p65
Nuclear Translocation
To assess p50 and p65 nuclear translocation BM-derived MDSC
were seeded onto poly-D-lysine coated glasses for 2 h in presence
of TM supernatants or LPS (10 ng/ml).
Cell permeabilization was obtained after 1 h incubation with
PBS 0.1% Triton-X100 (Sigma-Aldrich) plus 5% normal goat
serum (Dako Cytomation, Carpinteria, CA USA) and 2% BSA,
(Amersham Biosciences, Piscataway Township, NJ USA). Cells
were then incubated with rabbit anti-mouse p50 NF-kB (NLS,
sc-114; Santa Cruz) or rabbit anti-mouse p65 NF-kB (c-20,
sc-372; Santa Cruz). After 1h of incubation at RT, goat anti
rabbit AlexaFluor 488 conjugated (LifeTechnologies) were used
as secondary antibodies. Nuclei were counterstained with DAPI
(Invitrogen, Molecular Probes). Samples were mounted with
FluorPreserve Reagent (Calbiochem San Diego, CA USA) and
analyzed with a Leica SP8 I laser scanning confocal microscope
using a fine focusing oil immersion lens (40X, N.A. 1.3) at 1
Airy Unit resolution and operating in channel mode with 405
and 633 nm excitations. The mean fluorescence intensity of the
nucleus was quantified after a freehand drawing considering the
nucleus as regions of interest using Image-pro Premium 9.2.
In vitro PMN Cytostasis Assay
PMN were collected from blocks of 2% agarose and 0.2% gelatin
in saline 5 days after subcutaneous implant, as described (17).
PMN-mediated cytostasis was evaluated in a spectrophotometric
assay in 96-well microplates to be read on a microplate
spectophotometer. Briefly, after 72 h culture. cells were fixed with
5% formalin and stained with 1% methylene blue in 0.01M
borate buffer, pH 8.5. After eluting the dye from cells with 0.1N
HCl, absorbance was read at 620 nm. The percentage of growth
inhibition was calculated as [1–(A-B-C)/(D-C)] × 100, where A,
B, C, andD are absorbance of cultures of tumor cells and PMN, of
PMN alone, of 10∗4 target cells after adhesion for 2 h, and of the
dye in wells containing tumor cells cultivated for 72 hr. Results
are presented as mean (+SD) of three to six replicates.
Statistical Analysis
Statistical analysis of single treatments was performed using the
Mann-Whitney t-test. The significance of different combined
treatments was assessed through one-way ANOVA with Dunn’s
multiple comparison test. For other analyses related to MDSC
frequency or ELISA data, differences between groups were tested
for significance using a two-tailed unpaired t-test. Values were
considered statistically significant at p < 0.05. All of the analyses
were performed using Prism software Version 5.0d (GraphPad).
RESULTS
Frequency of MDSC in High-Grade Breast
Cancer Patients and Their Expression
of SPARC
The peripheral blood (PB) of high-grade breast cancer (BC)
patients (n = 12) was analyzed for the frequency of early-
stage MDSC (eMDSC), identified, by flow cytometry as Lin-
HLA-DR-CD33+CD11b+ [as described in (3)]. We found
that high-grade BC patients have a significantly increased
frequency of eMDSC if compared to healthy donors (HD)
(Figure 1A and Supplementary Figure 1A for gating strategy).
Using a different flow cytometry panel that includes HLA-
DR, CD33, CD11b, CD14, and CD15 (3, 28) it is possible
to define the PMN and M-MDSC subsets in BC patients,
being PMN-MDSC HLA-DR-, CD33+CD11b+CD15+ and M-
MDSC HLA-DR-CD33+CD11b+CD14+. According to this
panel we found that the vast majority of MDSC expanded
in BC patients are HLA-DR-CD33+CD11b+ CD14-CD15-
therefore not expressing the differentiation markers (Figure 1A
and Supplementary Figure 1B for gating strategy). However, the
few M-MDSC were increased in BC patients compared to HD
(Figure 1A).
To assess the expression of SPARC in circulating human
MDSC total HLA-DR-CD33+CD11b+ MDSC were FACS-
sorted and evaluated, by real-time (RT)-PCR and confocal
microscopy, for the expression of SPARC at RNA and protein
level, respectively (Figures 1B,C). RT-PCR analysis showed that
the expression of SPARC was significantly higher in MDSC
obtained from BC patients compared to HD (Figure 1B). In
line, confocal microscopy analysis confirmed SPARC expression
in MDSC of BC patients and less on the fewer HLA-DR-
CD33+CD11b+ cells obtained from one HD (Figure 1C).
To evaluate whether human myeloid cells express SPARC in
situ in the tumor microenvironment (TME) we performed a
double staining confocal microscopy analysis of BC paraffin
sections. The representative picture in Figure 1D shows SPARC
expression in CD33+ cells within the TME.
Next we moved to mouse models to assess whether also
murine MDSC express SPARC. To perform this analysis
we used 4 different mouse mammary tumors, previously
characterized for their different capacity to promote MDSC
expansion and activation (23). Indeed, these models were
used to demonstrate that SPARC over-expression in BC
cells support MDSC development and expansion. In detail,
SPARC-deficient (SN25A) or low expressing (N3D) did not
promoted MDSC expansion, whereas the SPARC-transduced
counterparts (SN25ASP and N3DSP) strongly supported
MDSC recruitment and suppressive capacity (23). Using
RT-PCR (Figure 1E) and immunofluorescence (IF, Figure 1F
and Supplementary Figure 1C, for the M-MDSC subset)
analyses we show that SPARC is expressed by both PMN- and
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FIGURE 1 | SPARC marks human and murine MDSC. (A) Cumulative FACS analysis showing the frequency of early MDSC (eMDSC), PMN- and M-MDSC, and
CD11b+CD33+CD14-CD15- in the PB of 12 consecutive BC patients. CD11b+CD33+ eMDSC were defined within HLA-DR-Lin- cell gate. The frequency of
e-MDSC was calculated as frequency of CD11b+CD33+ x Frequency of HLA-DR-/100. HLA-DR-CD33+CD11b+CD15+ PMN-MDSC and
HLA-DR-CD33+CD11b+CD14+ M-MDSC were identified within the CD11b+CD33+ gate. The CD11b+CD33+ gate was defined on HLA-DR- cells. HLA-DR+
cells were identified within the gate of live cells after doublets exclusion. The frequency of PMN and M-MDSC was calculated as Frequency of CD11b+CD33+ x
(Continued)
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FIGURE 1 | Frequency of CD14+ or CD15+/100. The gating strategies are shown in Supplementary Figure 1D. (B) Semiquantitative real-time PCR analysis for
SPARC and STAT3 performed on FACS-sorted MDSC isolated from breast cancer patients (BC PT; n = 5) compared to healthy donors (HD; n = 6);
(C) Representative confocal microscopy analysis showing SPARC (red) expression in FACS-sorted HLA-DR-CD33+CD11b+ cells from two representative BC
patients and one healthy control. (D) Representative confocal microscopy analysis for SPARC (green) and CD33 (red) showing the presence of CD33+ cells
expressing SPARC in representative BC patient paraffin sections (white arrows). One representative case is shown. Additional cases are shown in
Supplementary Figure 1. (E) Semiquantitative real-time PCR analysis for Sparc performed on murine MDSC subsets sorted from SN25A, SN25ASP, N3D and
N3DSP tumors. The Student’s t-test was used for statistical analysis (*p < 0.05; **p < 0.01). (F) Cytospin preparations of FACS-sorted PMN-MDSC isolated from
SN25ASP tumors and stained for Gr1 (green) and SPARC (red). The same staining for M-MDSC is shown in Supplementary Figure 1C.
M-MDSC dependently on concomitant tumor expression of
SPARC, being associate to N3DSP and SN25ASP, but not to
N3D and SN25A tumors. These data point to SPARC as a
potential new marker for MDSC. Notably, human BC samples
in which SPARC was absent on tumor cells were also devoid of
CD33+ cells expressing SPARC, in parallel with mouse results
(Supplementary Figure 1D).
Myeloid-Derived SPARC Is Required for
Epithelial-to-Mesenchymal Transition
To determine the relevance of SPARC when directly produced
by MDSC we took advantage from our SN25ASP and N3DSP
models in which we showed that the recruitment of MDSC
activates an EMT program in vivo but not in vitro (23).
SPARC-producing SN25ASP cells were injected into SPARC-
competent (WT) and SPARC-deficient (Sparc−/−) mice.
Histopathological analysis showed that tumors developing
into Sparc−/− mice had reduced EMT features than those
growing into WT recipients (Figures 2A,B). Indeed, in WT
mice the tumor mass was composed mainly by cells with
spindle morphology intermingled with abundant collagenic
matrix forming ill-defined nest-like infiltrates. On the contrary,
the EMT phenotype was almost entirely reverted in tumors
grown into Sparc−/− hosts that showed well-formed nest-like
ytumor structures stained for membrane-expressed E-cadherin
and reduced frequency of ZEB-1+ nuclei (Figures 2A,B).
These data demonstrated that the robust EMT observed in
SN25ASP tumors grown in WT mice was likely dependent on
microenvironment-derived SPARC. Notably, SN25ASP tumors
grew significantly less in Sparc−/− than WT mice (Figure 2C),
although in presence of reduced EMT. To test whether SPARC
produced endogenously by MDSC contributed to EMT, 106
MDSC isolated from the spleen of SN25ASP tumor-bearing WT
or Sparc−/− mice, were injected, once a week for 4 consecutive
weeks (Figure 2D), intra-tumorally into SN25ASP lesions grown
in Sparc−/− mice. Results show that SN25ASP tumors gained
the EMT marker ZEB-1 and lost E-cadherin, thanks to the
supplement of SPARC-producing MDSC, despite the SPARC-
deficiency in the host (Figures 2E,F). In presence of WT MDSC
we observed also an increased tumor growth (Figure 2G). The
data support the hypothesis that SPARC from MDSC is required
for immune-mediated EMT.
SPARC Specifies PMN-MDSC
Suppressive Functions
To test the functional relevance of SPARC expressed by MDSC,
PMN- and M-MDSC subsets were purified from the spleen
of tumor-bearing WT or Sparc−/− mice and evaluated for
their capacity to inhibit T cell proliferation in vitro. PMN-
MDSC from Sparc−/− mice had a marked reduced ability to
suppress T cell proliferation (Figure 3A). Comparison between
PMN- and M-MDSC subsets, in this model, was however
cumbersome being PMN-MDSC the population that expands
mostly in the spleen of tumor-bearing mice, accounting
for nearly 80% (77.8 ± 9.6) of the CD11b+ cells, in
comparison to the M-MDSC that account for 1% (1.10 ± 0.3).
Additionally, the expansion of PMN-MDSC (Ly6Ghigh cells)
in Sparc−/− hosts was even higher than in WT counterparts,
whereas the M-MDSC (Ly6C high cells) fraction was reduced
(Figures 3B,C).
To explain the reduced suppressive capacity of PMN-MDSC
from Sparc−/− vs. WT mice, we evaluated the expression of
genes that are involved in MDSC suppressive activity in FACS-
sorted MDSC from both tumors and spleens (29). Despite
their paucity, we also included FACS-sorted M-MDSC obtaining
enough material at least for RT-PCR analysis.
Expecting differences, we were surprised of finding similar
or higher expression of Stat3 and Arginase-I in Sparc−/−
MDSC (both from spleen and tumor) (Figure 3D and
Supplementary Figure 2). Different, however, was Nos2
that was higher in Sparc−/− than WT PMN-MDSC. NO, the
product of NOS2 activity, is a well-recognized pro-inflammatory
agent involved, for example, in ulcerative colitis. In support of
this idea, Tnf mRNA level was higher in Sparc−/− than WT
MDSC (Figure 3D).
Trying to explain the reduced suppressive activities of
Sparc−/− MDSC we evaluate ROS expression in total MDSC
(CD11b+ fraction, as described in Melani et al. (6) isolated from
the spleen of WT and Sparc−/− tumor-bearing mice. We found
a significantly decreased ROS expression by MDSC isolated fro
Sparc−/− hosts (Figures 3E,F).
To further study the mechanisms behind SPARC induction
of a pro-tumoral phenotype in MDSC, we look at NF-kB
signaling, as this pathway is involved in monocytes to M-
MDSC reprogramming (30–32). To test whether Sparc−/−
MDSC have defective NF-kB activation, we evaluated p65
and p50 translocation into the nucleus of BM-differentiated
MDSC (28) from WT and Sparc−/− mice, after exposure
to tumor supernatants or, as control, to LPS. Confocal
microscopy analysis revealed that SPARC-deficient MDSC
showed a significantly lower amount of p50 but not of p65
into the nucleus (Figure 3G and Supplementary Figure 3) than
SPARC-competent MDSC, at baseline or when in culture
with SN25ASP tumor supernatant (Figure 3G). This suggests
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FIGURE 2 | SPARC from MDSC supports EMT. (A) H&E and IHC analysis for E-cadherin and Zeb-1 markers performed in SN25ASP tumors obtained from WT and
Sparc−/− mice. Scale bars, 100µm. (B) Quantitative IHC data for EMT markers are shown as the fraction of positive nuclei for Zeb-1 (*p < 0.05; Unpaired T-test) in
tumors. (C) Mean tumor volume of SN25ASP tumors injected in WT and Sparc−/− mice. (D) Graphical abstract for the MDSC transfer experiment. (E) H&E and IHC
analysis for E-Cad and ZEB-1 showing the increased expression of EMT markers in SN25ASP tumors grown in Sparc−/− mice transferred with WT but not Sparc−/-
MDSC. (F) Quantitative IHC data for EMT markers are shown as the fraction of positive nuclei for Zeb-1. (G) Tumor Volume of SN25ASP tumors grown in Sparc−/−
mice transferred with MDSC from WT and SPARC-deficient mice.
that SPARC-deficient PMN-MDSC may be skewed toward an
inflammatory phenotype.
Endogenous SPARC Reverts
Tumor-Induced PMN Education
Toward Cytostasis
Inflammatory PMN, isolated from subcutaneous agar-implants,
exert cytostatic activity toward G-CSF releasing tumor cells (17).
Using inflammatory PMN isolated fromWT and Sparc−/− mice,
we evaluated whether tumor cells, according to their ability to
promoteMDSC differentiation (SN25ASP> SN25A), can inhibit
such PMN function and whether PMN from SPARC-competent
and -deficient mice are differently susceptible to tumor induced
re-education and therefore capable of different cytostatic activity
on tumor cells. To this end PMN from WT or Sparc−/− mice,
were co-cultured with SN25A or SN25ASP tumor cells. Both
SN25A and SN25ASP cells lines express G-CSF at similar level,
whereas they release different amounts of GM-CSF, IL-6 and
COX-2, all significantly higher in the SPARC-over-expressing cell
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FIGURE 3 | SPARC-deficient MDSC are less suppressive than WT counterparst. (A) Immunosuppressive activity of PMN-MDSC isolated from the spleens of WT and
Sparc−/− tumor-bearing mice evaluated as the ability to suppress a-CD3/a-CD28-induced CD4 and CD8T cell proliferation in vitro. (B) FACS analysis of CD11b+,
PMN- and M-MDSC performed on peripheral blood of WT and Sparc−/− mice injected with the SN25ASP cell line. The Student’s t test was used for statistical
analysis (*p < 0.05). (C) IHC analysis of the myeloid markers Gr-1 and Ly-6C performed on WT and Sparc−/− tumors, showing the enrichment in Gr-1+ cells in
Sparc−/− tumors. Scale bars, 100mm. (D) Semiquantitative real-time PCR analysis for Stat3, Arginase1, Nos2 and Tnf genes performed on PMN-MDSC and
(Continued)
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FIGURE 3 | M-MDSC subsets sorted from SN25ASP tumors grown in WT and Sparc−/− mice (n = 4 for per group). The Student’s t test was used for statistical
analysis (*p < 0.05; **p < 0.01). (E) Representative histogram plots for ROS detection in WT and Sparc−/− MDSC. Oxidation of the cell-permeant dye by ROS
generate a bright green fluorescence detectable at FACS in the FITC channel. (F) Cumulative day showing ROS production by MDSC in terms of percentage of cells
oxidating the dye and therefore expressing ROS or the MFI of expression of the oxidated permanent dye. (Student t-test **p< 0.01). (G). Quantitative data showing
p50 and p65 nuclear translocation in MDSC differentiated in presence of G-CSF, GM-CSF, and IL-6 from the BM of WT and Sparc−/− mice. MDSC were culture for
2 h in presence of SN25ASP tumor supernatants or LPS (*p < 0.05; ***p < 0.001).
line (23). Co-culturing these cells with PMN we found that WT
PMN had cytostatic activity only against SN25A cells, whereas
they were significantly less cytostatic when co-cultured with
SN25ASP cells (Figure 4A). Sparc−/− PMN were similarly able
to inhibit the growth of SN25A cells (Figure 4A) but contrarily
to WT PMN, were also able of cytostasis against SN25ASP cells
(Figure 4A). These results suggest that SPARC, endogenously
produced by MDSC, contributes to tumor-induced education
of myeloid cells toward a pro-tumoral phenotype. In line with
the pro-inflammatory, anti-tumor activity of myeloid cells from
Sparc-deficient mice, histological analysis of SN25ASP grown in
Sparc−/− mice showed features of stromal and vascular damages
with vascular lacunae characterized by infiltrating granulocytes
undergoing lytic activities (Figure 4B).
Altered Tumor Vascularization in
SPARC-Deficient Hosts
MDSC can support tumor growth also promoting angiogenesis,
for example through the production of VEGF. We investigated
whether SPARC can influence tumor angiogenesis as part of their
pro-tumorigenic activities. We evaluated VEGF expression by
RT-PCR in spleen and tumor MDSC from WT and Sparc−/−
mice and the serum level of VEGF in SN25ASP tumor-
bearing Sparc−/− mice, receiving or not a transfer of WT
or Sparc−/− MDSC. Vegf mRNA expression was higher in
Sparc-deficient PMN-MDSC and M-MDSC (Figure 5A), as it
was the amount of VEGF in the serum of Sparc−/− mice
injected with Sparc-deficient rather thanWTMDSC (Figure 5B),
suggesting that the lack of SPARC in MDSC may favor tumor
vascularization. However, IHC analysis of tumor sections showed
a reduced staining of CD31, a marker of endothelial cells, in
Sparc−/− than in WT mice (Figures 5C,D). Therefore, despite
a potential increase in tumor angiogenesis because of higher
VEGF availability, the concomitant pro-inflammatory nature of
Sparc−/− PMN likely limits the formation of an efficient vascular
network. In favor of this interpretation, IHC analysis performed
onto tumor sections shows the presence of PMN destroying
the vascular wall of CD31+ vessels (Figure 5E). Overall these
results point to less suppressive Sparc−/− MDSC, endowed
with cytostatic activities, and of the capacity of damaging
tumor vasculature, thus explaining the reduced growth of tumor
implanted into Sparc−/− mice.
The Absence of SPARC Increases
Neutrophil Extracellular Trap Extrusion
by PMN-MDSC
NETs are extruded by activated PMNafter exposure to a variety of
factors (i.e., immune complexes, IFNs, TNF and others). Recently
it has been shown that NETs can be extruded byMDSCwithin the
TME via IL-8 stimulation (33). This finding prompted us to assess
whether the absence of SPARC could impact NET formation by
MDSC expanded in presence of a tumor. To this end PMN-
MDSC were isolated from the spleen of tumor-bearing Sparc−/−
and WT mice, seeded onto poly-D-Lysine coated glasses and
stimulated or not with PMA to induce NETosis. We observed
that MDSC from tumor-bearing WT and Sparc−/− mice were
equally able to extrude NETs in presence of PMA, but in its
absence only MDSC isolated from Sparc−/− mice were able to
extrude NETs (Figure 6). This might suggest that the sensing of
different specific factors or the lack of some brakes produced
in vivo in the absence of SPARC could differently prime PMN-
MDSC for NET formation.
DISCUSSION
Myeloid cells expand within the bone marrow and migrate into
the periphery where they are skewed toward MDSC.
We propose that SPARC expression in MDSC is required
for their pro-tumor “education.” In the absence of endogenous
SPARC, MDSC are indeed less suppressive and have reduced
capacity to sustain EMT and tumor outgrowth. The reduced
suppressive capacity was particularly evident on PMN-MDSC.
However, due to the very low amount of M-MDSC in our
mammary tumor models we were unable of testing whether
SPARC could also influence the activity of the monocytic
subset. Although not subverting numerically the PMN-MDSC,
in the majority of mouse tumor models a prevalent function
is given to M-MDSC (34). However, in few cases the relevance
of the suppressive activity of PMN-MDSC has been clearly
shown (4). Furthermore, other matricellular proteins have
been demonstrated relevant for immunosuppression, such as
osteoactivin, also known as glycoprotein nonmetastatic B
(GPNMB) (35) and intracellular ostepontin (iOPN) (27).
Different transcription factors have been involved in the
acquisition of MDSC suppressive phenotype, among which
the best-characterized are STAT3, STAT1 and NF-kB. STAT3
works preferentially on PMN-MDSC and is largely involved in
MDSC expansion. In our models, Arginase-I and NOS2, whose
expression can be controlled by STAT3, were surprisingly not
down-regulated in Sparc−/− MDSC, which are low suppressive.
Flow cytometry analysis showed equal phosphorylation of STAT3
in WT and Sparc−/− MDSC. Also, STAT1, which contributes
to suppression, was equally phosphorylated in MDSC from the
two strains. Although in contrast with the expected immune
suppression, the high STAT3 pathway found in Sparc−/− MDSC
is in line with the increased VEGF that is regulated by, but
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FIGURE 4 | In the absence of SPARC PMN display increased cytostatic activity over tumor cells. (A) PMN-mediated cytostatic activity against SN25A and SN25ASP
cells. Bars represent the PMN-mediated growth inhibition, means +/- SD of triplicate are shown (*p < 0.05). (B) H&E analysis showing PMN infiltrating granulocytes
undertaking lytic activity (arrows) on both tumor cells and vascular structures.
also regulate, STAT3 (36, 37). We have already described that
VEGF expandsMDSC suggesting that STAT3may concur to both
suppression and expansion of MDSC, but through uncoupled
mechanisms (6). Thus, in Sparc−/− mice MDSC expansion can
largely depend on VEGF, whereas other mechanisms can account
for the reduced MDSC suppression, in presence of key mediators
like Stat3, Nos2, and Arginase1. Searching for possible relevant
differences between Sparc−/− and WTMDSC we found reduced
nuclear translocation of the NF-kB p50 subunit, in the former.
This may suggest that reduced level of p50 subunits may limit
the formation of immunosuppressive p50:p50 homodimers in
favor of the p65:p50 inflammatory heterodimers. Supporting
this hypothesis, the production of TNF by Sparc−/− MDSC
was significantly higher than by WT MDSC. Furthermore, very
recently Veglia et al. reported that the deletion of the fatty acid
transport protein 2 (FATP2) abrogated the suppressive activity
of PMN-MDSC leaving unaffected the expression of Arginase 1
andNos2 (4). This discrepancy in expression of suppressive genes
and MDSC suppressive activity was explained showing reduced
PGE2 production by PMN-MDSC from Fatp2-KO compared to
WT mice. We previously shown that the intracellular retention
of SPARC in tumor cells through the over-expression of SCD5,
an enzyme that mediated the synthesis of monounsatured fatty
acids (MUFA), suppressed tumor growth through an alteration
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FIGURE 5 | Increased VEGF expression in MDSC from Sparc−/− mice. (A) Semiquantitative real-time PCR analysis for Vegf performed on PMN-MDSC and
M-MDSC subsets sorted from SN25ASP tumors grown in WT and Sparc−/− mice (n = 4 for per group). The Student’s t-test was used for statistical analysis (***p <
0.001) (B) Representative IHC analysis for CD31 of SN25ASP tumors grown in WT and Sparc−/− mice (*p < 0.05; **p < 0.01) (C) Quantification of the vessel areas
calculated as (CD31+ area/total tumor area)*100. (D) Representative IHC analysis for CD31 in SN25ASP tumor sections from Sparc−/− mice. (E) The representative
picture highlights the presence of PMN (box) destroying the vessel wall.
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FIGURE 6 | Increased NET formation by Sparc−/− MDSC in comparison to WT counterpart. Representative IF analysis showing increased presence of NETs (white
arrows) in Sparc−/− MDSC seeded onto poly-D-Lysine coated glasses in presence of the DNA dye Sytox green.
of satured and monounsatured FA balance. The last impacted
on tumor growth and metastasis (38). It is reasonable that
knocking-down SPARC in MDSC would result in an alteration
of FA balance that might ultimately impact on PMN-MDSC
functions, as occurred in the case of Fatp2-KO mice. Differently
from Veglia et al. (4) we found that PMN-MDSC isolated from
the spleen of tumor-bearing WT and Sparc−/− mice showed a
strongly reduced ROS expression in those from Sparc−/− mice.
However, our findings are in line with the role of fatty acids in the
induction of cytosolic and mitochondrial reactive oxygen species
(ROS) (38).
Overall these results suggest that the reduced ROS expression
combined to the high production of TNF could account for the
anti-tumor activity of Sparc−/− myeloid cells.
In fact although associated with tumor-induced chronic
inflammation (39), TNF if produced at high doses becomes a
key factor in mediating tumor-rejection (40). Therefore, it is
foreseeable that an unbalance in TNF production could skew
MDSC toward an inflammatory, anti-tumor phenotype. Notably,
TNF is also required for inflammation-driven NETosis. Indeed,
we previously showed impaired NET formation in TNF-KO
mice (16) and high TNF in Sparc−/− MDSC might explain
their increased spontaneous NET formation obtained in vitro
by seeding MDSC onto poly-D-lysine coated glasses. In vivo,
spontaneous NETosis was observed mainly in the case of SN25A,
a Sparc-null tumor when injected into Sparc-deficient mice, and
less in the case of SN25ASP tumors. The likely explanation
should consider that NET formation is negatively regulated
by collagens (via LAIR-1) and that collagen is more abundant
in SPARC-transduced tumors. This context, associated with a
robust inflammatory environment of Sparc−/− mice, exacerbates
NET formation and their pathogenicity in vivo. As occurring
in systemic vasculitis (41), in which NETs promote endothelial
damage, we found sign of vascular damages in tumors grown in
Sparc-deficient mice.
Unexpectedly, despite the influence of MDSC-derived SPARC
on EMT markers and immune suppression, the tumor volume
of SN25ASP tumors injected in WT and Sparc −/− mice was
similar at the end, although the differed kinetics of growth
that was initially faster in WT mice. Several years ago we
published that neutrophils can control tumor growth and favor
the elicitation of anti-tumor immune responses (42). Our data
suggest that PMN-MDSC from Sparc−/− mice behave as N1-like
neutrophils rather than MDSC, a condition that allows them to
initially control tumor growth until other immune suppressive
mechanisms take over (i.e., CD8T cells exhaustion). Indeed,
tumors injected in Sparc−/− mice show higher infiltration by
CD8T cells characterized by the expression of multiple markers
of exhaustion (not shown).
These results prompt the hypothesis that NET could come
in different flavors, according to the context in which they are
generated, to sustain either pro-tumor or anti-tumor immunity.
An additional level of complexity is introduced by the ECM,
as the amount of collagen influences NET formation, despite
the presence of an inflammatory environment suitable for such
an event.
In conclusion, this paper proposes SPARC as a new potential
marker of MDSC, in both human and mouse, with the additional
feature of controlling MDSC suppressive activity with the aim of
preventing an excessive anti-tumor inflammatory state.
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